Biofrontera Inc. BFRI 深 滬
交易中 03-26 11:35:14 美东时间
0.8125
-0.011
-1.34%
華盛通- 最 高0.8229
- 今 開0.8143
- 成交量 1.13万股
- 最 低 0.812
- 昨 收 0.8235
- 總市值 946.42万
- 52周最高 1.19
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.536
- 委 比 -11.11%
- 總股本 1164.83万
- 歷史最高 292.60
- 量 比 0.20
- 振 幅 1.32%
- 歷史最低 0.536
- 每 手 1
- 風險率 0.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多电话会总结 ｜ Biofrontera(BFRI)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Biofrontera业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **季度表现（2025年Q4）：** - 营收达到1,710万美元，创公司历史新高，同比增长36% - 净利润560万美元，较上年同期140万美元净亏损实现扭亏为盈 - 调整后EBITDA为490万美元，较上年同期负140万美元大幅改善630万美元 - 毛利率提升至82%，较上年同期58%显著改善 **全年表现（2025年）：** - 年度营收4,170万美元，同比增长12% - 净亏损1,050万美元，较上年1,780万美元净亏损改善41% - 调整后EBITDA
03-20 12:31
Biofrontera Earnings Call: Profits Rise, Risks Remain
Biofrontera, Inc. (($BFRI)) has held its Q4 earnings call. Read on for the main...
03-20 08:09
Biofrontera Q4 EPS $0.48 Beats $0.20 Estimate, Sales $17.100M Beat $16.146M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly earnings of $0.48 per share which beat the analyst consensus estimate of $0.20 by 146.15 percent. This is a 352.63 percent increase over losses of $(0.19) per share from the
03-20 05:49
Biofrontera reports rise in Q4 revenue, turns profitable
Biofrontera (BFRI) reported record Q4 2025 revenue of $17.1M, up 36% year-over-year. Gross margin surged to 82.4%, driven by improved cost structure after its transaction with Biofrontera AG. The comp...
03-20 03:18
Dermatology drugmaker Biofrontera's Q4 revenue rises to record high on Ameluz strength
Dermatology drugmaker Biofrontera's Q4 revenue rises to record high on Ameluz strength Overview US biopharma firm's Q4 revenue rose 36% yr/yr to record high, driven by Ameluz sales Company posted Q4 net income of $5.6 mln, reversing prior-year loss Gross margin improved to 82.4% in Q4, reflecting lo
03-19 21:36
BRIEF-Biofrontera Q4 Revenue USD 17.1 Million
BRIEF-Biofrontera Q4 Revenue USD 17.1 Million Mar 19 (Reuters) - Biofrontera Q4 net income USD 5.6 million. Q4 adjusted EBITDA USD 4.9 million Q4 operating expenses USD 12.5 million
03-19 21:25
Biofrontera Q4 2025 gross margin jumps 24.4 percentage points to 82.4% on revenue up 36% to USD 17.1 million
Biofrontera Q4 2025 gross margin jumps 24.4 percentage points to 82.4% on revenue up 36% to USD 17.1 million Biofrontera published a financial results press release reporting record Q4 and FY 2025 results and a business update. Q4 revenue rose 36% to USD 17.1 million, while gross margin expanded 24.
03-19 21:25
Earnings Scheduled For March 19, 2026
Companies Reporting Before The Bell • Neuraxis (AMEX:NRXS) is projected to repo...
03-19 19:11
Biofrontera Reports Positive Phase 2b Acne Trial Results
An announcement from Biofrontera ( ($BFRI) ) is now available. On March 9, 2026...
03-09 21:49
Biofrontera Inc. Reports Positive Phase 2b Results Supporting Further Development of Ameluz® Photodynamic Therapy for moderate to severe Acne Vulgaris
Biofrontera Inc. announced positive results from its Phase 2b clinical trial of Ameluz® PDT for moderate to severe acne vulgaris. The 3-hour incubation regimen showed superior efficacy, reducing inflammatory lesions by 57.97% vs. 36.51% with vehicle. Safety and tolerability were favorable, with most adverse events mild to moderate. Patient satisfaction was high, with 85.7% willing to undergo PDT again. Acne vulgaris presents a promising new indic...
03-09 13:15
